#$%^&*AU2020203417A120200611.pdf#####H: nterwoven NRPortbI DCC GRS 20242750 I.DOCX-25/05/2020 COMBINATION OF ANTI-CD20 ANTIBODY AND P13 KINASE SELECTIVE INHIBITOR ABSTRACT Highly effective combinations of a compound of formula A (a P13K6 selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amelioration of haematological malignancies such as leukemia and lymphoma.WO 2014/071125 1/12 PCT/US2013/067956 0 C 0 C'C, 0) CD ~ cc co -0 0) 00 CD a) CN CD 0 D ~ / M) CD C U)D C)Y C) _ -aD 06 C) 00 E C) _00 C) 0 U) CD, j~5 ~.- CD CDCU) 01 00 U)0 0 CL 0) 0D 0 -~ CD 0 CN C)Z D 0 UO!7d1IIC6W3
